Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BI-3406 + Sotorasib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BI-3406 | HY-125817|EX-A3418|BI3406|BI 3406 | SOS1 Inhibitor 16 | BI-3406 binds to SOS1 thus prevents SOS1 interaction with Kras-GDP, resulting in inhibition of Kras downstream signaling and potential inhibition of tumor cell growth (AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct 2019, Abstract PL06-01, PMID: 32816843). | |
Sotorasib | Lumakras | AMG 510|AMG510|AMG-510|Lumykras | KRAS G12C inhibitor 34 | Lumakras (sotorasib) is small molecule inhibitor that selectively targets KRAS G12C and inhibits downstream signaling, which may lead to growth inhibition of tumors harboring KRAS G12C (PMID: 31666701). Lumakras (sotorasib) is FDA approved for use in patients with locally advanced or metastatic non-small cell lung cancer harboring KRAS G12C who have received one or more prior therapy (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|